Evidence map›Paper›PMID 40055949›Full record

ArticleActa ophthalmologica2025

Visual outcome including visual field defects after treatment of paediatric optic pathway glioma: A nationwide cohort study.

C A M Bennebroek, J van Zwol, M C Montauban van Swijndregt, S E Loudon, A L W Groot, N J C Bauer, J W Pott, I C Notting, A J van Sorge, M M van Genderen and 4 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta ophthalmologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

C A M BennebroekDepartment of Ophthalmology, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.ORCID https://orcid.org/0000-0002-4733-2120
J van ZwolDepartment of Ophthalmology, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
M C Montauban van SwijndregtDepartment of Ophthalmology, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
S E LoudonDepartment of Ophthalmology, Rotterdam, Erasmus MC University Medical Center, Rotterdam, The Netherlands.
A L W GrootDepartment of Ophthalmology, Radboud University Medical Center, Nijmegen, The Netherlands.
N J C BauerDepartment of Ophthalmology, Maastricht University Medical Center, Maastricht, The Netherlands.
J W PottDepartment of Ophthalmology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID https://orcid.org/0000-0003-0860-1356
I C NottingDepartment of Ophthalmology, Leids University Medical Center, Leiden, The Netherlands.
A J van SorgeRoyal Dutch Visio, National Foundation for the Visually Impaired and Blind, Huizen, The Netherlands.
M M van GenderenDiagnostic Center for Complex Visual Disorders, Bartiméus, Zeist, The Netherlands.ORCID https://orcid.org/0000-0002-9286-8397
P de GraafDepartment of Radiology and Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
A Y N Schouten-van MeeterenDepartment of Neuro-Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands.
P SaeedDepartment of Ophthalmology, University of Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands.
G L PorroDepartment of Ophthalmology, University Medical Center Utrecht, Utrecht, The Netherlands.

Funding

ODAS Stichting 2019-01
6 · The paper itself

Abstract

purposeTo examine long-term visual impairment and visual field examination (VF) after diverse treatments for paediatric optic pathway glioma (OPG), and to determine prognostic factors for long-term severe visual impairment or blindness.

methodsA nationwide retrospective cohort study (1995-2018) was performed on paediatric OPGs that received various (successive) therapies. The analysis of severe VI or blindness was represented by the outcome of both BCVA and VF testing. Prognostic factors for long-term severe VI or blindness were identified.

resultsData on BCVA and VF were available in 117 of 136 children (86.0%) who received treatment. After a median follow-up of 8.3 years (range: 0.1-23.8 years) after the start of treatment, severe VI or blindness (>1.0 LogMAR) was observed in both eyes in 18.8% of 117 patients and in 34.6% of 234 included eyes. This impairment was more common in sporadic OPGs. Monocular VF defects were present in 80.0% of a subgroup of 110 eyes (47.0%), predominantly represented by hemianopia in 69.3% and various scotomas in 28.4%. Independent prognostic factors for severe VI or blindness included starting therapy under the age of 2 years and hypothalamic involvement of the OPG.

conclusionIn this study, long-term binocular severe VI or blindness appeared in almost one in five patients and in one in three eyes after diverse treatment for paediatric OPG. Visual field data were available in only one in two children; VF defects were present in four out of five eyes. Children starting therapy under the age of 2 years were particularly at risk for long-term severe VI or blindness. Future prospective studies need to include VF analysis as an outcome parameter and should analyse treatment effects on both monocular and binocular BCVA.

Indexed as

Optic Nerve GliomaOptic Nerve NeoplasmsVision DisordersVisual AcuityVisual FieldsAdolescentChildChild, PreschoolFemaleFollow-Up StudiesHumansInfantMalePrognosisRetrospective StudiesVisual Field Testsblindnesschildlow‐grade gliomaoptic pathway gliomatreatmentvisual fieldvisual impairment

Identifiers

PMID40055949
PMCPMC12340183

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.